Which mitigation strategy is commonly used to reduce LASA confusion between similar drug names?

• A. Tall-man lettering.
• B. Unified color-coding only.
• C. Reducing labels.
• D. Eliminating barcodes.

Answer: (A)

The main idea is to make look-alike drug names easier to distinguish by emphasizing the parts that differ. Tall-man lettering does this by using mixed case within a drug name—uppercase letters in the middle of the word—to draw attention to the differences between similar names. This visual cue helps clinicians pause and compare before selecting, dispensing, or administering a medication, which reduces the chance of confusing two drugs that sound alike or look alike.

This approach is widely recommended because it directly targets how people read and recognize names in fast-paced settings, where a quickly read label or screen could be mistaken for another. It can be applied across prescriptions, labeling, electronic order entry, and packaging to create a consistent cue that helps prevent LASA errors.

Color-coding alone isn’t enough to reliably distinguish drug names, since color perception can vary and doesn’t change the letter patterns that cause confusion. Reducing labels would remove important information needed for safe use, and eliminating barcodes would remove a crucial verification step during dispensing and administration. Tall-man lettering specifically addresses the name-recognition issue at the point of decision, making it the best-known mitigation for LASA confusion.